Good morning, everyone, and welcome to the Milestone Scientific 2023 Year-End Financial Results and Business Update Conference Call. It is now my pleasure to turn the floor over to your host, David Waldman, Investor Relations of Milestone Scientific. Sir, the floor is yours.

Good morning and thank you for joining Milestone Scientific's 2023 year-end financial results conference call. On the call with us today are Arjan Haverhals, Chief Executive Officer; and Keisha Harcum, Vice President of Finance at Milestone Scientific. The company issued a press release today, April 1, 2024, containing 2023 year-end financial results, which is also posted on the company's website. If you have any questions after the call or would like any additional information about the company, please contact Crescendo Communications at (212) 671-1020. The company's management will now provide prepared remarks reviewing the financial and operational results for the year ended December 31, 2023. Before we get started, we would like to remind everyone that during this conference call, we may make forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, and future success. These statements involve a number of risks and uncertainties and are based upon assumptions involving judgments with respect to future economic, competitive, and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's report on Form 10-K for the year ended December 31, 2023. The forward-looking statements made during this call are based upon management's reasonable belief as of today's date, April 1, 2024. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. With that, we'll now turn the call over to Arjan Haverhals, Chief Executive Officer. Please go ahead, Arjan.

Thank you, David, and thanks to everyone for joining us today. I'm pleased to report that we achieved solid financial results in 2023 with revenue increasing 12% to $9.8 million. We also reported an increase in gross profit of 39% for the full year 2023 to $6.8 million. I'm especially proud to report that our dental operating income increased by 90% to $2.1 million in 2023. This strong margin improvement and improved profitability within our Dental division were due in large part to our streamlined operations and the success of our new portal for selling and shipping the FDA single-tube anesthesia system and hand pieces directly to Dental Clinics and Dental Service Organizations or DSOs within the U.S. We achieved solid growth despite 2023 being a transitional year, having terminated the agreement with a prior distributor Henry Schein at the end of 2022. We also terminated all nonexclusive agreements with other distributors in the U.S. in September 2023. We didn't make that decision lightly, and in hindsight, this was the right decision. I'm confident our new strategy is working and anticipate enhanced benefits from this transition to a direct model in 2024. Establishing a closer and more direct relationship with our dental customers has not only improved margins but has also allowed us to do a much better job selling and providing outstanding customer service, which has led to much greater stickiness and repeat orders within existing clients. Since the launch of the portal, we have been able to track sales data and conduct sales analysis. We now know the customer's identity and purchase patterns, enabling us to really improve sales execution with existing customers and reactivate dormant customers in the U.S. In addition, we have implemented educational programs to enhance the customer experience as well as maximize the relationship over time. This direct relationship allows us to provide the necessary training and ongoing support to ensure continued usage by dentists and hygienists. Importantly, this approach has proven effective within individual practices, Dental Service Organizations, and large group practices. The direct sales model provides greater interaction with the customer and a higher level of support for both large and small practices. In turn, this has helped attract premier customers. For example, we added the Main Dental Group to our growing roster of Dental practices, which includes 21 practices across the Northeast and United States. Additionally, we commenced direct sales to Meridian Endo Imperial, a large endodontics, periodontics, and implant dentistry practice with 3 offices in Wisconsin. This includes the deployment of the FDA in needs of their operatory rooms and across all the endodontists and periodontists within the practice. These latest agreements illustrate the benefits of our new sales strategy and our ability to cost-effectively scale the business by adding large dental practices. We also believe that having such prestigious large group practices will help shorten our sales cycle and enable us to aim at further penetration of the DSO and large group practice market going forward. We are clearly executing our new sales strategy with a much leaner sales organization, allowing us to enhance our margins and maximize profitability. We are also rolling out a variety of marketing initiatives to drive greater awareness of our technology among dental practices nationwide. Specifically, we have engaged in more direct-to-consumer marketing. These activities have resulted in leads from dentists contacting us directly to order our instruments because patients requested them to do so. We will continue to increase our marketing efforts with dedicated campaigns directly targeted at patients. While our international sales pulled back slightly, this was largely due to the timing of orders, certain distributors working through inventory, and our focus on the domestic markets. We also made a decision to pull back from China until market conditions improve. That said, we expect to resume solid international business heading into 2024 and continue to add new international partners which should support our global expansion strategy. On a final note, we are on track with our next-generation dental instrument and look forward to unveiling it in the near future. It's also worth reminding everyone that our Dental division continues to operate profitably. As I mentioned earlier, the Dental business generated over $2.1 million of operating income, which is a 90% increase over the same period last year. So to summarize, within our Dental business, through our new direct sales strategy and our increased marketing efforts, we aim to further grow our Dental business in the coming quarters. As we continue to grow our revenues, we expect to benefit from economies of scale as well as the recurring nature and high margins on our disposables. Turning to our Medical division, we are also advancing the rollout of our CompuFlo Epidural System. Specifically, we have made significant progress in penetrating key hospitals, health care systems, and pain management clinics. We are also witnessing existing customers expand their use of CompuFlo. An important example is UTMB Health Clear Lake Campus Hospital, which has commenced the use of the CompuFlo beyond labor and delivery to now include neurostimulation spinal cord stimulator implantation procedures, illustrating the versatility and broad potential of our instrument. The spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain. An estimated 60,000 spinal cord stimulators are implanted each year. This implies a potential company revenue of $18 million alone in this segment. We need to remind ourselves that the total market of epidural injections is $11 million. Assuming a 20% penetration in this market, that is equivalent to $80 million in net profits on the consumables for the company on an annual basis. Approval and adoption of the technology for neurostimulation spinal cord stimulator implantation followed a successful evaluation process by Dr. Patrick Karas, a full-time faculty Neurosurgeon at UTMB, who operates at both the Galveston and Clear Lake campuses. Dr. Karas completed 10 cases using CompuFlo, in which he reported 100% clinical success and no complications. I'm pleased to report that further expansion of our technology at UTMB is underway. CompuFlo has proven to be of tremendous assistance in performing spinal cord stimulator cases. Specifically, CompuFlo helps to minimize the risk of intraoperative cerebrospinal fluid leakage and trauma to underlying nerve roots, both potential complications of spinal cord stimulator procedures. Cerebrospinal fluid leakage can require a postoperative blood patch, whereas nerve root irritation can cause severe reticulitis requiring extended postoperative admission and postoperative steroid injections. CompuFlo has also decreased operative time, one of the major hospital cost drivers, by around 20 minutes per procedure according to clinician feedback. Most recently, we commenced sales of CompuFlo Epidural disposables to Omaha Pain Physicians, a comprehensive medical pain management center in Omaha, Nebraska. This approval follows an extensive trial and evaluation by Dr. Matthew Stottle, its Founder and Medical Director. Dr. Stottle completed 10 cases using CompuFlo at Omaha Pain Physicians, in which he reported 100% clinical success. Evaluation included epidural steroid injection procedures within the lumbar, thoracic, and cervicothoracic junction of the spine. As more and more physicians and anesthesiologists perform procedures and submit for reimbursement, our goal is to secure coverage for our technology as we continue to execute on our goal of establishing CompuFlo to become the standard of care in epidural analgesia. I'd now like to take a moment to provide an update on our reimbursement strategy. We are making good progress in advancing our broad reimbursement strategy through a carefully staged approach. We are working closely with key pain management providers in the use of the new CPT tracking code for accurate and timely CompuFlo claims submission. Additionally, we are providing support to the clinical facilities for each individual claim to have an appropriate response. We have established sites across the U.S. that are actively utilizing CompuFlo and submitting claims to payers across the country. Rather than spreading ourselves thin by bringing on too many hospitals and clinics before reimbursement approval, we realized it was better to focus on working closely with a handful of pain clinics and provide them the necessary professional support to help ensure positive payer reimbursement. We are supporting these clinicians' utilization of the CompuFlo across a variety of use cases, which is important in demonstrating widespread utilization of the technology. Use of our system by these providers follows successful evaluation periods by the clinics and physicians. In each case, they reported 100% success with zero dural punctures. I'm pleased to report that our clinical sites have submitted claims for over 45 patient procedures in the first 3 months of 2024 alone, which is nearly half of the claims we submitted in all of 2023. All claims submitted to date using the CPT 0777T code have been uploaded by payer systems for processing. Claims are being submitted to Medicare as well as commercial payers. We are encouraged by the high level of claim activity that is being generated by pain management providers, which provides Milestone the opportunity to indirectly engage with payers to educate them on the CompuFlo technology and help build support for the appropriate level of reimbursement from insurance providers. Review and analysis of 100 claims data indicated that roughly 1/3 of claims have already received payment. More than half of these payments were paid by commercial payers followed by Medicare. Moreover, we have initiatives underway that we believe will help build support for broad reimbursement of the CompuFlo. Clinicians have the opportunity to engage with Medicare jurisdictions prior to the final payment position of the jurisdiction. Turning to the international front, we are expanding our network of distribution partners for CompuFlo. In November, we announced a distribution agreement with Bioline Supply to distribute the CompuFlo and disposables across Spain. Spain represents an important market for us with a population in excess of 48 million people and a growing number of epidural procedures each year in pain management and anesthesiology. Overall, we are targeting independent distributors with existing relationships within key global markets and proven track records of introducing medical devices within their territories. We look forward to announcing additional partners as we expand our global footprint. We also believe there is a market opportunity for CompuFlo within federal and other government agencies as our system can contribute to both improved patient outcomes as well as increased efficiency. As we have discussed in the past, we are advancing initiatives following SEM approval and work closely to secure approval within the federal supply schedule. FSS approval would open up the sizable government market. So to summarize, we are continuing our efforts to seed the market with our technology among key physicians, which we believe will ultimately translate into adoption. We remain committed to our goal of establishing the CompuFlo as the new standard of care in epidural anesthesia by providing patients with effective pain relief while reducing the risk of complications.

Thank you, Arjan. For the year ended December 31, 2023 and 2022, revenue was approximately $9.8 million and $8.8 million, respectively, an increase of approximately $1 million. The company launched an e-commerce platform selling and shipping the STA, single tooth anesthesia system and hand pieces directly to end users, including dental offices and dental groups within the U.S. E-commerce revenue for the year ended December 31, 2023, was approximately $4.8 million. The company ended the agreement with its major U.S. distributor Henry Schein as of December 31, 2022. The company recorded no revenue for Henry Schein for the year ended December 31, 2023, compared to approximately $2.6 million recorded for the year ended December 31, 2022. Revenue from other U.S. distributors was approximately $485,000 for the year ended December 31, 2023, a decrease of $97,000 compared to December 31, 2022. The company also terminated all nonexclusive agreements with other distributors in the U.S. in September of 2023. For the year ended December 31, 2023, international revenue was approximately $4.1 million, a decrease of $724,000 compared to December 31, 2022. Gross profit for the year ended December 31, 2023 was $6.8 million versus $4.9 million for the year ended December 31, 2022. The increase in gross profit was due to higher margin sales with the launch of the new online portal. Operating losses for the year ended December 31, 2023, were $7.1 million versus $8.8 million for the year ended December 31, 2022. The decrease in loss from operations was driven by higher dental sales and increased margins, offset by higher selling, general and administrative expenses during the period. Net loss was approximately $6.9 million or $0.10 per share for the year ended December 31, 2023, versus a net loss of $8.7 million or $0.12 per share for the comparable period in 2022. Now, I'd like to turn your attention to liquidity and capital resources. We continue to carefully manage expenses and have maintained a solid balance sheet. At December 31, 2023, the company had cash and cash equivalents and marketable securities of approximately $6 million, working capital of $7.7 million and no long-term debt.

Thank you, Keisha. As Keisha mentioned, we continue to maintain a strong balance sheet with approximately $6 million of cash, cash equivalents, and marketable securities as of December 31, 2023, which we believe provides us more than sufficient capital to execute on our sales and marketing activities around both our Dental and Medical instruments without the need for additional funds. We also expect to receive a large payment from the tech selling on the New Jersey operating loss program. We expect this will further enhance our balance sheet. In addition to our revenue growth and improved margins, we also reduced our loss from operations by over $1.7 million. Through our new dental sales strategy, including our online store and our enhanced marketing efforts, we are increasing domestic sales at higher margins. Although our primary focus in 2023 was on the domestic front, we have renewed our international focus heading into 2024. That said, we expect to resume solid business going forward. Our Dental business continues to generate positive cash flow on a stand-alone basis. As we continue to grow our revenues, we expect to benefit from economies of scale due to the recurring nature and high margins on our disposables. We believe we have developed a scalable platform to drive our Dental instrument and handpiece sales in the coming year. The Medical segment represents a large addressable market, as I said, 11 million procedures, 20% penetration would result in $80 million of net profit on the consumables alone on an annual basis for the company. And we remain confident in our belief that CompuFlo will ultimately become the standard of care, given both the safety advantages and cost savings to the providers and payers. These factors coupled with our reimbursement strategy should ultimately lead to increased sales and adoption of the CompuFlo system. Within our Medical segment, we continue to add prominent hospitals and pain management clinics as well as expand our international business partners. Most importantly, we are making progress advancing our reimbursement strategy around the CompuFlo system. We are also advancing initiatives following the SAM approval and leading up to potential federal supply system approval, which would open up the sizable government market. So to wrap up, we are witnessing growing interest in both our Dental and Medical instruments and we believe we are well-positioned to take advantage of the opportunities available in the market. At the same time, we continue to streamline our operating structure and remain committed to driving shareholder value. We look forward to providing further updates as developments unfold. Overall, we are encouraged by the outlook for the business and look forward to executing on a number of key initiatives in 2024 that we believe will drive significant value for our shareholders.

Your first question is coming from Anthony Vendetti from Maxim Group.

This is actually Jeremy on the line for Anthony. So just 2 questions. First, on the Dental side, I know you mentioned multiple times in the call that you're planning to reintroduce or push forward back into the international markets. Does that include reentering the China market? And also maybe if you could just talk a little bit of and maybe some more detail around the strategy going forward to re-enter a bigger place into these international markets.

Okay. Thank you, Jeremy. The strategy for the Dental business, as we alluded on, is to continue to grow the platform business in the United States, because for reasons that I have alluded to, there's a high offtake potential and that's where the growth in the Dental business domestically should come from. That's also the reason why we terminated at the end of September last year all nonexclusive distributors in the United States—because that would bring us more revenues moving forward simply due to a price-volume mix effect. The international business strategy is actually based on two things. First, what you have to do and what we have been doing in the past but even more so last year is looking in the segmentation of the distributors we have, divide them into groups. So you have an A, B, and C segment. In A, that's the highest tier where, let's say, 90% of our business is coming from. That's about 15 distributors. A middle group, we have developed programs to develop those distributors and grow those distributors from smaller revenues to larger revenues. Then your question on reentering China, I do not foresee that we have any commercial activities in China, simply based on the fact that the market conditions are not in favor for us. Historically, we have been in China for instruments and hand pieces, but the market situation changed to that extent that we are not entering low-margin business in the Chinese market. Does that answer your question?

Yes, that was really helpful. And then jumping to the Medical side, it's really good news that this claim submissions that seem to be picking up some speed, especially in the first quarter in 2024 and I assume that we could expect that to continue through the rest of 2024. Just you mentioned 1/3 of the claims submitted have received payments. Maybe you can provide a little information around what are the other 2/3s. Are you waiting for that? Have some of those been denied? And if they had been denied, what's your strategy for appeal?

Okay. So in the others, like I said, all claims have been uploaded. So that means that there is coverage by insurance providers for these procedures. We have not received 100% permanent denials by any of these insurance providers. To your point, the other 2/3 that is still in processing. What we did with the first 100 claims, you have to take that over time. We are very encouraged about the feedback when we did the data analysis. We see an increase in the number of cases of these 100 claims plus the 42 claims moving forward. So, long story short, they have been offloaded. The code has been uploaded in the system, of which we are aware. Yes, we are continuously adding other clinics and clinicians because we want to increase utilization and the volume. In case of your last part of the question, denial or appeal, of course, what we do every time when the office manager or the coding manager of the clinicians reaches out to us and they want to appeal, we can provide more information about the technology, send in duplicates of the invoice that they have to submit to the insurance providers, all to come to a final position of one of these jurisdictions to state that they are willing to pay for our technology, for the cases—use cases on steroid injection at a certain price. We are following the process, and I'm extremely pleased and positive and confident, and also impressed by our team and our organization, how they have been able to drive this forward as a smaller entity because there are numerous companies that have not been following the pathway that we are doing and have not had the initial success that we are facing today. So I remain very confident about this whole process and getting payment at a certain price level by the providers.

Great. And then just last question. Is the plan for 2024 to start approaching commercial payer coverage and try and use the data that you're getting from these claims submissions and the data that you have already about the savings the money that...

No, absolutely. I think—absolutely. So twofold. I think what people need to understand is the acceptance for spinal cord stimulators at UTMB following the entire process that is tremendous, because it is not related to any reimbursement in the hospital for these procedures since the neurosurgeons see a direct clinical, financial, and efficiency benefit of using our technology. So as we speak, I know that we have applied in other hospitals as well for these procedures. But based on previous calls, like I always said, there is a value assessment committee. But having said that, that it has been accepted by UTMB, it will have a triggering effect on other hospitals as well. The second part is the commercial approach. Absolutely on the—for example, just motor vehicle cases is a tremendous source of revenue for clinicians. I cannot explain the amount of money because I'm not entitled to do so. But I would say covering one or two motor vehicle cases will potentially cover the cost of one box of consumables of the CompuFlo Epidural system. So in other words, we are using that as well in the commercial rollout, where we can get more sites to actively engage and help us drive volume moving forward. I know that we are in a number of clinics that we are currently running trials with and also hospital systems. So there will be more to come and we will share that in the future with everybody on the phone and with all the shareholders of the company and investors as well.

Thank you. That concludes our Q&A session. I will now hand the conference back to David Waldman for closing remarks. Please go ahead.

We'll actually turn the call back over to management for that. Thank you.

Thank you all for taking the time and listening to this conference call. I highly appreciate your support. Please do not hesitate to reach out to us directly with any questions you might have. Like we said, management is positive about the outlook, and is proud of what we have been able to establish. We are following the process and we look forward to sharing more news with you in the not-too-distant future when these developments unfold. So having said that, have a great day, stay safe, and looking forward to talking to you in the near future. Bye-bye.

Thank you everyone, that concludes today's event. You may disconnect at this time and have a wonderful day. Thank you for your participation.